FIELD: medicine, pharmaceutics.
SUBSTANCE: there are presented the use of polydatine for treating toxic (including drug-induced) and alcoholic hepatic diseases, as well as based oral compositions. What is shown is reduction of a degree of hepatocyte adipose degeneration in sub-acute alcoholisation, reduction of glycemia and lactate-acidosis. Polydactine promoted reduction of synthesis and accumulation of glycosaminoglycans.
EFFECT: invention may be used for treating toxic hepatitis, including of drug-induced and alcoholic nature; hepatic adipose degeneration (hepatic steatosis), including of nonalcoholic fatty liver disease (steatohepatitis); hepatic cirrhosis.
4 cl, 1 dwg, 2 tbl
